Original reporting and analysis on the stories shaping biotech.
BridgeBio's acoramidis just posted real-world data showing it outperformed Pfizer's entrenched tafamidis in nearly 2,700 heart patients. In a market worth billions, the new kid on the block is making a very compelling case.
TRex Bio just went public with $117 million and Eli Lilly as its biggest shareholder, all to boost the immune system's own peacekeeping cells. The Treg therapy space is heating up fast, and the race to reinvent autoimmune treatment is officially on.
GSK's mRNA flu vaccine just beat both standard and high-dose flu shots in a mid-stage trial of 971 adults. Now it's heading to Phase 3, putting GSK squarely in Moderna's rearview mirror in the race to reinvent the annual flu shot.
uniQure's Huntington's gene therapy looked like a breakthrough at three years, with a 75% slowing of disease progression. Then the four-year data arrived, the statistical significance vanished, and the stock cratered nearly 40% in a single day.
Iovance just bumped its 2026 revenue guidance by $55 million for a cancer therapy that requires custom-building each patient's treatment from their own tumor. The company that wasn't supposed to scale is scaling fast, and the entire cell therapy industry is watching.
The FDA just approved the first herpes antiviral with a new mechanism of action in nearly 30 years. It's not for cold sores; it's for immunocompromised patients who ran out of options, and the clinical data is striking.
Merck KGaA is spending $11.3 billion in cash to buy Bio-Techne, the company behind 400,000 antibody types and 6,000 proteins used in labs worldwide. It's one of the biggest life sciences tools deals of the year, and analysts are split on whether the hefty price tag will pay off.
Eli Lilly showed that combining its psoriasis drug Taltz with weight-loss blockbuster Zepbound doesn't just treat two diseases at once; it may unlock an entirely new biological response. The data hint at a future where obesity and autoimmune disease stop being treated as separate problems.
Bayer is dropping $2.2 billion on its first-ever pharma manufacturing campus in North America, picking New Albany, Ohio, as the site for a massive bet on domestic drug production. It's part of a reshoring tidal wave that's rewriting the rules of where medicine gets made.
Foghorn Therapeutics axed 40% of its workforce after its Eli Lilly-partnered cancer drug flopped in Phase 1. The $1.6 billion collaboration is over, the stock is at $2, and the wreckage tells a cautionary tale about one of oncology's trickiest frontiers.
Merck is dropping $10 billion to buy Verona Pharma and its first-in-class COPD drug, ensifentrine. With Keytruda's $33 billion revenue stream facing patent expiration in 2028, this deal is less about lungs and more about survival.
The FDA just agreed to let Wave Life Sciences pursue accelerated approval for an RNA editing therapy, something that's never happened before in this emerging field. The implications stretch far beyond one rare disease.
The U.S. government is launching a cancer vaccine initiative modeled on Operation Warp Speed, and Moderna's stock surged 14% on the news. But with 70x less funding than its pandemic predecessor, can a $200 million bet really change the game?
CRISPR Therapeutics just landed a coveted late-breaking slot at AHA 2026 for its one-shot gene-editing heart therapy, CTX310. The Phase 1b data could answer whether permanently silencing a single gene is the future of cardiovascular medicine.
Iambic Therapeutics dropped a new 41-billion-parameter AI model, a $40 million AbbVie deal, and an $800 million IPO filing all on the same day. It's either the most coordinated flex in AI biotech history or the ultimate test of whether Wall Street will buy what AI drug discovery is selling.
The FDA just approved a monthly olanzapine shot for schizophrenia that doesn't require post-injection monitoring, a first for the drug. Teva's Weltruza could reshape how one of psychiatry's most effective (but logistically frustrating) medications actually gets used.
An AI startup just convinced six of the world's biggest pharma companies to partner up in nine months flat. Chai Discovery's secret weapon? Its protein-folding models actually work when you test them in real labs, not just on screens.
FDA review documents rattled Revolution Medicines investors by hinting its pancreatic cancer drug works better in some patients than others. Meanwhile, Zealand Pharma's obesity drug delivered solid results that would've been impressive five years ago, but in the age of GLP-1 blockbusters, "solid" doesn't cut it.
Life Biosciences just shared the first-ever human data for a cellular reprogramming therapy, and two of three glaucoma patients showed vision improvements. It's tiny and early, but this could be the moment aging biology stopped being theoretical.
Novo Nordisk just dropped up to $1.3 billion on a tiny Swedish company's atom-by-atom coating technology. The goal: turning weekly GLP-1 shots into monthly or quarterly injections, which could reshape the entire obesity and diabetes market.
Thermo Fisher just dropped $8.9 billion on a clinical trial data company most people have never heard of. The twist? Clario's platform has quietly touched 70% of all novel drugs approved by the FDA and EMA over the past decade.
Argenx got a clinical trial failure and a clinical trial win on the same day. The Sjögren's disease flop sent shares tumbling double digits, while quietly promising celiac data got lost in the wreckage.
Join thousands of biotech professionals who start their day with our free, daily briefing.